<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00743925</url>
  </required_header>
  <id_info>
    <org_study_id>AN-CVD2224</org_study_id>
    <nct_id>NCT00743925</nct_id>
  </id_info>
  <brief_title>FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes</brief_title>
  <acronym>FRANCIS-ACS</acronym>
  <official_title>FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anthera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anthera Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of A 002 when added to&#xD;
      high dose atorvastatin in subjects with an acute coronary syndrome (ACS)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind randomized parallel group placebo controlled study in subjects&#xD;
      presenting with an ACS. Subjects will be randomized to receive either A 002 500 mg once daily&#xD;
      (QD) or placebo tablets in addition to 80 mg atorvastatin QD.&#xD;
&#xD;
      Randomization must occur within ≤96 hours of hospital admission for the index ACS event, or,&#xD;
      if already hospitalized, within ≤96 hours of index event diagnosis. Follow-up visits will&#xD;
      occur at Weeks 2, 4, 8, 12, 16, 20, and 24 post-randomization; and monthly thereafter until&#xD;
      study completion.&#xD;
&#xD;
      All enrolled subjects will remain on treatment until all subjects have been treated for a&#xD;
      minimum of 24 weeks or until the occurrence of a Major Adverse Cardiac Event (MACE). At that&#xD;
      point, all active subjects (those who have not early withdrawn or those that have not already&#xD;
      had a MACE) will be brought in for a Final Study Visit. Subjects who complete the Final Study&#xD;
      Visit may be eligible to enroll in an open-label extension study for up to 2 years total&#xD;
      study drug exposure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percent changes in LDL hs-CRP, sPLA2 and other biomarkers will be compared between the 2 treatment groups.</measure>
    <time_frame>8 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The occurrence of MACEs will be examined for any treatment-related trends at study completion.</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">625</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A-002 (500 mg QD) plus Atorvastatin (80 mg QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo tablets plus Atorvastatin (80 mg QD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varespladib Methyl (A-002)</intervention_name>
    <description>2 Tablets (250 mg each) once daily for at least 24 weeks in combination with Atorvastatin (80 mg tablet once a day).</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>A-002</other_name>
    <other_name>Varespladib</other_name>
    <other_name>Lipitor</other_name>
    <other_name>Atorvastatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women ≥18 years of age&#xD;
&#xD;
          -  A diagnosis of unstable angina, NSTEMI, or STEMI&#xD;
&#xD;
          -  Any one of the following criteria: Diabetes, CRP ≥2 mg/L, or metabolic syndrome&#xD;
&#xD;
          -  Subjects must be randomized within 96 hours of the index event&#xD;
&#xD;
          -  Percutaneous revascularization, if required or planned, must occur prior to&#xD;
             randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Subjects must NOT meet any of the following exclusion criteria:&#xD;
&#xD;
          -  Subjects enrolled in another experimental (interventional) protocol within the past 30&#xD;
             days prior to Screening.&#xD;
&#xD;
          -  Subjects treated for cancer within the previous 5 years except for skin basal cell&#xD;
             carcinoma or carcinoma in situ of the cervix, with measures other than a minor,&#xD;
             complete surgical excision (e.g., chemotherapy), or radiation therapy.&#xD;
&#xD;
          -  The presence of severe liver disease with cirrhosis, recent active hepatitis, active&#xD;
             chronic hepatitis, ALT or AST &gt;3 x ULN, biliary obstruction with hyperbilirubinemia&#xD;
             (total bilirubin &gt;2 x ULN)&#xD;
&#xD;
          -  Active cholecystitis, gall bladder symptoms, or potential hepato-biliary abnormalities&#xD;
&#xD;
          -  The presence of severe renal impairment (CrCl &lt;30 mL/min or creatinine &gt;3 x ULN),&#xD;
             nephrotic syndrome, or patients undergoing dialysis&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus (HbA1c &gt;11% within the last 1 month prior to Screening)&#xD;
&#xD;
          -  Females who are nursing, pregnant, or intend to become pregnant during the time of the&#xD;
             study, or females of child-bearing potential who have a positive pregnancy test during&#xD;
             screening evaluation. Women of child-bearing potential must also use a reliable method&#xD;
             of birth control during the study and for 1 month following completion of therapy. A&#xD;
             reliable method for this study is defined as one of the following: oral or injectable&#xD;
             contraceptives, IUD, contraceptive implants, tubal ligation, hysterectomy, a barrier&#xD;
             method (diaphragm with spermicidal foam or jelly, or a condom).&#xD;
&#xD;
          -  Subjects who have a history of alcohol or drug abuse within 1 year of study entry&#xD;
&#xD;
          -  Subjects living too far from participating center or unable to return for follow-up&#xD;
             visits&#xD;
&#xD;
          -  Subjects who in the opinion of the Investigator are a poor medical or psychiatric risk&#xD;
             for therapy with an investigational drug, are unreliable, or have an incomplete&#xD;
             understanding of the study which may affect their ability to take drugs as prescribed&#xD;
             or comply with instructions&#xD;
&#xD;
          -  Known HIV, Hepatitis B or C virus, or tuberculosis infection&#xD;
&#xD;
          -  Acute bacterial, fungal or viral infection&#xD;
&#xD;
          -  Any current statin therapy at maximum recommended dosage. For atorvastatin,&#xD;
             fluvastatin, lovastatin, pravastatin and simvastatin 80 mg QD at the time of the index&#xD;
             event and for rosuvastatin 20 mg QD to 40 mg QD&#xD;
&#xD;
          -  Drugs that are potent inhibitors of cytochrome P450 unless they can be withdrawn&#xD;
&#xD;
          -  Subjects with NYHA Class III or IV heart failure, or LVEF &lt;30&#xD;
&#xD;
          -  Subjects with moderate or severe aortic stenosis, aortic regurgitation, mitral&#xD;
             stenosis or mitral regurgitation&#xD;
&#xD;
          -  Ventricular arrhythmias requiring chronic drug treatment or ICD&#xD;
&#xD;
          -  Subjects with no stenosis or stenosis &lt;50% on angiography&#xD;
&#xD;
          -  Subjects with a pacemaker or persistent LBBB&#xD;
&#xD;
          -  LDL-C &gt;200 mg/dL (5.2 mmol/L)&#xD;
&#xD;
          -  Fasting triglyceride levels of ≥400 mg/dL (4.5 mmol/L)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardiological hospital of The Patriarchate of all Georgia</name>
      <address>
        <city>Tbilisi</city>
        <zip>0102</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tbilisi State Medical University, Al. Aladashvili University Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0102</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardio Reanimation Centre</name>
      <address>
        <city>Tbilisi</city>
        <zip>0141</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiological Clinic &quot;Guli&quot;</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tbilisi LTD Cardiology Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Cardiology Center by acad. G. Chapidze</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center of Therapy</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Clinical Hospital of Tbilisi #2</name>
      <address>
        <city>Tbilisi</city>
        <zip>0164</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Services Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limited Company &quot;ADAPTI&quot; The Clinic of Angiocardiology &quot;ADAPTI&quot;</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hospital Medical Union</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Healthcare Institution</name>
      <address>
        <city>Gatchina</city>
        <zip>188300</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Healthcare Institution</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-State Healthcare Institution</name>
      <address>
        <city>Kemerovo</city>
        <zip>650055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk Medical Academy</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Intstitution of Moscow</name>
      <address>
        <city>Moscow</city>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital №12</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Healthcare Institution</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630008</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional State Healthcare Institution</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Healthcare Institution</name>
      <address>
        <city>Perm</city>
        <zip>614107</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Healthcare Institution</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>190000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Healthcare Institution</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>191144</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Healthcare Institution</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>198205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Healthcare Institution</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution</name>
      <address>
        <city>Samara</city>
        <zip>443070</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical University</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution</name>
      <address>
        <city>St-Petersburg</city>
        <zip>195197</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Healthcare Institution</name>
      <address>
        <city>St-Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution for Further Professional Training</name>
      <address>
        <city>St.Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Healthcare Institution</name>
      <address>
        <city>St.Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution Research Cardiology Institute</name>
      <address>
        <city>Tomsk</city>
        <zip>634012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyumen Cardiology Center,</name>
      <address>
        <city>Tyumen</city>
        <zip>625026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Clinical Hospital No. 27</name>
      <address>
        <city>Kharkiv</city>
        <zip>61002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology of Central Clinical Hospital</name>
      <address>
        <city>Kharkiv</city>
        <zip>61018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L.T. Malaya Institute of Therapy of AMS of Ukraine</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kharkiv Medical Academy of Post-Graduate Education</name>
      <address>
        <city>Kharkiv</city>
        <zip>61178</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital #1</name>
      <address>
        <city>Kyiv</city>
        <zip>02175</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Scientific Center</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Danylo Halytsky National University</name>
      <address>
        <city>Lviv</city>
        <zip>79000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Regional State Clinical Treatment and Diagnostics Cardiology Center</name>
      <address>
        <city>Lviv</city>
        <zip>79015</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzhgorod National University</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zaporizhzhya Regional Cardiological Dispensary</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhytomyr city hospital #1</name>
      <address>
        <city>Zhytomyr</city>
        <zip>10002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>http://www.anthera.com/</url>
    <description>Sponsor's Website</description>
  </link>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>August 27, 2008</study_first_submitted>
  <study_first_submitted_qc>August 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2008</study_first_posted>
  <disposition_first_submitted>January 31, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>January 31, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 2, 2012</disposition_first_posted>
  <last_update_submitted>January 30, 2014</last_update_submitted>
  <last_update_submitted_qc>January 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unstable Angina</keyword>
  <keyword>STEMI</keyword>
  <keyword>NSTEMI</keyword>
  <keyword>ACS</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>C14.280.647.124</keyword>
  <keyword>C14.280.647.500</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Varespladib methyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

